---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-23-000003"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T13:08:49.509159+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# LivaNova RECOVER depression trial enrollment to continue to 450 patients per DSMB advice

## Summary
- Independent Statistical Analysis Committee advised enrollment continue from 425 to 450 unipolar patients.
- Trial remains on track; interim analyses every 25 patients assess predictive probability of success.
- If successful, results could support peer-reviewed article and CMS reimbursement reconsideration for VNS Therapy.
- No efficacy or safety signal disclosed; trial continues per protocol.

## SEC filing metadata
- accession: 0001639691-23-000003
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000003/0001639691-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969123000003/livn-20230118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-23-000003
- JSON: https://secwatch.observer/filing/0001639691-23-000003.json
- Plain text: https://secwatch.observer/filing/0001639691-23-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.